Literature DB >> 29284546

Medical Emergencies Related to Ethanol and Illicit Drugs at an Annual, Nocturnal, Indoor, Electronic Dance Music Event.

Paul Calle1, Nora Sundahl1, Kristof Maudens2, Sarah Mr Wille3, Diederik Van Sassenbroeck4, Koen De Graeve5, Stefan Gogaert6, Peter De Paepe1, Dieter Devriese7, Geert Arno8, Peter Blanckaert9.   

Abstract

Introduction Medical problems are frequently encountered during electronic dance music (EDM) events. Problem There are uncertainties about the frequencies and severity of intoxications with different types of recreational drugs: ethanol, "classical" illicit party drugs, and new psychoactive substances (NPS).
METHODS: Statistical data on the medical problems encountered during two editions of an indoor electronic dance event with around 30,000 attendants were retrieved from the Belgian Red Cross (Mechelen, Belgium) database. Data on drug use were prospectively collected from the patient (or a bystander), the clinical presentation, and/or toxicological screening.
RESULTS: In the on-site medical station, 487 patients were treated (265 in 2013 and 222 in 2014). The most frequent reasons were trauma (n=171), headache (n=36), gastro-intestinal problems (n=44), and intoxication (n=160). Sixty-nine patients were transferred to a hospital, including 53 with severe drug-related symptoms. Analysis of blood samples from 106 intoxicated patients detected ethanol in 91.5%, 3,4-methylenedioxymethamphetamine (MDMA) in 34.0%, cannabis in 30.2%, cocaine in 7.5%, amphetamine in 2.8%, and gamma-hydroxybutyric acid (GHB) in 0.9% of patients (alone or in combination). In only six of the MDMA-positive cases, MDMA was the sole substance found. In 2014, the neuroleptic drug clozapine was found in three cases and ketamine in one. Additional analyses for NPS were performed in 20 cases. Only in one agitated patient, the psychedelic phenethylamines 25B-NBOMe and 25C-NBOMe were found.
CONCLUSIONS: At this particular event, recreational drug abuse necessitated on-site medical treatment in one out of 350 attendants and a hospital transfer in one out of 1,000. Ethanol remains the most frequently abused (legal) drug, yet classical illicit recreational drugs are also frequently (co-) ingested. The most worrying observation was high-risk poly-drug use, especially among MDMA users. Regarding NPS, the number of cases was low and the clinical presentations were rather mild. It should be stressed that these observations only apply to this particular event and cannot be generalized to other EDM events. Calle P , Sundahl N , Maudens K , Wille SMR , Van Sassenbroeck D , De Graeve K , Gogaert S , De Paepe P , Devriese D , Arno G , Blanckaert P . Medical emergencies related to ethanol and illicit drugs at an annual, nocturnal, indoor, electronic dance music event. Prehosp Disaster Med. 2018;33(1):71-76.

Entities:  

Keywords:  EDM electronic dance music; GC-MS gas chromatography-mass spectrometry; GHB gamma-hydroxybutyric acid; HPLC high-performance liquid chromatographic; ILT I LOVE TECHNO; MDMA 3; NPS new psychoactive substances; THC tetrahydrocannabinol; 3; 4-methylenedioxymethamphetamine; 4-methylenedioxymethamphetamine (MDMA); ethanol; illicit drugs; mass gatherings; rave party

Mesh:

Substances:

Year:  2017        PMID: 29284546     DOI: 10.1017/S1049023X17007099

Source DB:  PubMed          Journal:  Prehosp Disaster Med        ISSN: 1049-023X            Impact factor:   2.040


  2 in total

1.  Predicting medical usage rate at mass gathering events in Belgium: development and validation of a nonlinear multivariable regression model.

Authors:  Hans Scheers; Hans Van Remoortel; Karen Lauwers; Johan Gillebeert; Stijn Stroobants; Pascal Vranckx; Emmy De Buck; Philippe Vandekerckhove
Journal:  BMC Public Health       Date:  2022-01-25       Impact factor: 3.295

2.  Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review.

Authors:  Jan van Amsterdam; Tibor M Brunt; Mimi Pierce; Wim van den Brink
Journal:  Neurotox Res       Date:  2021-09-23       Impact factor: 3.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.